BIOMAT Database Logo BIOMAT Database Logo

[Combination chemotherapy of advanced Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone]. 1991

N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
Department of Clinical Oncology, Cancer Institute Hospital.

Thirty-three patients with advanced Hodgkin's disease were treated with a combination chemotherapy consisting of vincristine 1 mg/m2 iv on day 1, 8, cyclophosphamide 500 mg/m2 iv on day 1, procarbazine 100 mg/m2 p.o. day 1-7, and prednisolone 40 mg/m2 p.o. day 1-7. Twenty patients received this regimen every 4 weeks (VCPP II regimen). Furthermore, we conducted higher dose intensive VCPP II-2 regimen which was repeated every two weeks for thirteen patients. Complete response rate of both regimens was 63% (VCPP II 45%, VCPP II-2 85%). The median duration of CR was 37 + months. Leukopenia, neurotoxicity and gastrointestinal toxicity were commonly observed but were clinically manageable. These results indicate that high dose intensive chemotherapy is effective for achieving high CR rate for advanced Hodgkin's disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma

Related Publications

N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
[Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
November 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
[Combination chemotherapy with vincristine, cyclophosphamide, procarbazine and prednisolone in advanced reticulum cell sarcoma (author's transl)].
July 1976, [Rinsho ketsueki] The Japanese journal of clinical hematology,
N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
Testicular dysfunction after cyclophosphamide-vincristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin's disease. A long-term follow-up study.
May 1990, Cancer,
N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
[Alternating chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP); etoposide, procarbazine, vindesine and prednisolone (EPVP) as a treatment for advanced-stage Hodgkin's disease].
March 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
[Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].
May 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
[Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (VEPA) for non-Hodgkin's lymphoma].
January 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas.
March 1976, Cancer,
N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
Combination therapy with cyclophosphamide, vincristine, procarbazine and prednisone in Hodgkin's disease and reticulum cell sarcoma.
January 1971, Medicina,
N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine.
July 1966, British medical journal,
N Mizunuma, and M Ogawa, and Y Kuraishi, and N Horikoshi, and K Inoue, and T Mukaiyama, and H Fukutani, and M Tabata, and A Hirano, and S Itami
Oat cell carcinoma of the lung: combination chemotherapy with cyclophosphamide, vincristine and procarbazine.
January 1977, Clinical bulletin,
Copied contents to your clipboard!